Article Information
History
- July 5, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Johannes C. Michaelian1,*,
- Christopher C. Rowe2,
- Susan E. Kurrle3,
- Constance Dimity Pond4,
- Michael Woodward5 and
- Sharon L. Naismith1,*
- 1Healthy Brain Ageing Program, Brain and Mind Centre and Charles Perkins Centre, School of Psychology, Faculty of Science, University of Sydney, NSW, Australia
- 2Department of Molecular Imaging and Therapy, Austin Health, The University of Melbourne, Victoria, Australia
- 3Faculty of Medicine and Health, University of Sydney, Sydney, Australia
- 4Wicking Dementia Research and Education Centre, University of Tasmania
- 5Department of Continuing Care, Austin Health, The University of Melbourne, Victoria, Australia
- ↵*Corresponding authors:
Johannes C. Michaelian, Brain and Mind Centre, 94 Mallett Street, Camperdown NSW 2050, Australia, Email: johannes.michaelian{at}sydney.edu.au Tel.: +612 9351 0621, Sharon L. Naismith, Brain and Mind Centre, 94 Mallett Street, Camperdown, NSW 2050, Email: sharon.naismith{at}sydney.edu.au Tel.: +612 9351 0781
Posted July 05, 2024.
Is Australia ready for the rollout of amyloid-targeting therapies for Alzheimer’s disease? Results from a national survey characterising current infrastructure capability, workforce and training needs of memory and cognition clinics
